Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

CRANBURY, N.J., Sept. 22, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter and fiscal year ended June 30, 2011.  

Recent Highlights

  • Palatin initiated enrollment in its Phase 2B trial with bremelanotide in premenopausal women with female sexual dysfunction.
  • Palatin announced commencement of a Phase 1 trial of AZD2820, under development for treatment of obesity, in collaboration with AstraZeneca.
  • In March 2011, Palatin closed on a $23.0 million firm commitment public offering consisting of 23 million units at a price to the public of $1.00.  Net proceeds to Palatin after deducting underwriting discounts and other offering expenses were $21.0 million.

  • Fourth Quarter and Fiscal Year End 2011 ResultsPalatin reported a net loss of $3.3 million, or $(0.09) per basic and diluted share, for the quarter ended June 30, 2011, compared to a net loss of $4.2 million, or $(0.40) per basic and diluted share, for the same period in 2010.The change in net loss for the quarter ended June 30, 2011 compared to the net loss for the quarter ended June 30, 2010 was primarily attributable to $1.3 million of non-cash, non-operating income, which represents the decrease in estimated fair value of the warrant liability from March 31, 2011 through May 11, 2011, the date the warrants ceased to be classified as a liability upon stockholder approval of the increase in authorized common stock

    Palatin's net loss for the year ended June 30, 2011 was $12.8 million, or $(0.64) per basic and diluted share, compared to a net loss of $1.8 million, or $(0.18) per basic and diluted share, for the year ended June 30, 2010.  

    The change in net lo
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
    2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
    3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
    4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
    5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
    6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
    7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
    8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
    9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
    10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
    11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... Pa. , July 25, 2014 /PRNewswire-iReach/ -- ... and consulting for global corporations operating in highly ... host its first annual Global User Group Conference, ... historic Philadelphia, Pennsylvania at ... - http://photos.prnewswire.com/prnh/20140724/130263 This ...
    (Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
    (Date:7/24/2014)... Calif. , July 24, 2014  Now available ... to home. Rehealth Regenerative Therapies , located in ... and other physically active people a new health option: ... Regardless of age, countless patients suffer from joint ... activities, such as muscle tears, torn rotator cuff, tennis ...
    (Date:7/24/2014)... Security forces worldwide rely on sophisticated equipment, trained ... other public areas against terrorist attacks. A revolutionary ... about to make their job much easier. , ... Patolsky of Tel Aviv University ,s School of ... developed by the Herzliya company Tracense, picks up ...
    Breaking Biology Technology:Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Nano-sized chip 'sniffs out' explosives far better than trained dogs 2
    ... , , , ... became the only hospital in the Midwest to acquire a dual console ... States to purchase the new system. , , ... the latest robotic-assisted surgery system that gives surgeons an enhanced three-dimensional view ...
    ... , , , , ... Inc. (Nasdaq: RGDX ) announced today that it has entered ... Partnership to raise approximately $4 million from the private placement of 3,057,907 ... $1.30 per share. The closing of the sale of the shares occurred ...
    ... , , , ... (NYSE: ARE ), Landlord of Choice to the Life ... long-term lease with Eli Lilly and Company as the anchor tenant ... Science Park ("the Alexandria Center"). Lilly has leased approximately 91,000 ...
    Cached Biology Technology:St. John's Hospital Acquires Latest Technology in Robotic-Assisted Surgery 2Response Genetics Announces $4 Million Private Placement 2Response Genetics Announces $4 Million Private Placement 3Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology 2Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology 3Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology 4
    (Date:7/24/2014)... 24, 2014) Scientists at The New York ... step closer to creating a viable cell replacement ... cells. , For the first time, NYSCF ... from skin samples of patients with primary progressive ... protocol to induce these stem cells into becoming ...
    (Date:7/24/2014)... Bushmeat, the use of native animal species for food ... be a significant factor in the decline of many ... new study indicates that more than half of the ... raptors and hornbills., "By surveying not only the meat ... being eaten inside the forest by hunters and brought ...
    (Date:7/24/2014)... current biodiversity, the product of 3.5 billion years of ... history of life. But it may be reaching a ... literature and analysis of data published in Science ... loss and decline of animals is contributing to what ... sixth mass biological extinction event. , Since 1500, more ...
    Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3
    ... pay more for meals prepared with produce and meat ... meals actually increases when the price increases, according to ... of how customers perceive and value local food shows ... when they are priced slightly higher than meals made ...
    ... a poorly understood class of RNA produced in a mammal,s ... of the infection. Their findings are reported today in ... Microbiology. RNA (ribonucleic acid) contains information transcribed from the ... these RNAs translate sections of DNA code into building blocks ...
    ... New University of Florida research puts to rest the ... glacial period. It turns out it ended up in the ... findings have implications for modern-day global warming, said Ellen Martin, ... paper, which is published in this week,s journal Nature ...
    Cached Biology News:Restaurant customers willing to pay more for local food 2New class of biomolecules triggered in response to respiratory virus infection 2New class of biomolecules triggered in response to respiratory virus infection 3New class of biomolecules triggered in response to respiratory virus infection 4UF research gives clues about carbon dioxide patterns at end of Ice Age 2UF research gives clues about carbon dioxide patterns at end of Ice Age 3
    Screening assay to detect the Listeria monocytogenes in food samples by,DNA amplification and molecular hybridization on a microtiter plate....
    ... CopyControl™ vector can be induced prior to ... provide the stability of single-copy BACs with ... other cloning vectors. The kits provide the ... insert size screening system) necessary to create ...
    ... PCR Enhancer (with betaine) substantially improves ... and specificity for amplification of many ... in PCR eliminates the base-pair composition ... thermal stability, suppresses pauses of DNA ...
    ... Systems provide rapid, precise localization of ... frozen or paraffin-embedded tissue, cytospins and ... facilitate double or triple labeleing experiments, ... with primary antibodies of different animal ...
    Biology Products: